Published in final edited form as:

Psychoanal Psychother. 2010 December 1; 24(4): 306–314. doi:10.1080/02668734.2010.519234.

THE ONGOING STRUGGLE FOR PSYCHOANALYTIC RESEARCH: SOME STEPS FORWARD

Fredric N. Busch, M.D. and

Clinical Associate Professor of Psychiatry, Weill Cornell Medical College, Faculty, Columbia University Center for Psychoanalytic Training and Research, New York, New York

Barbara L. Milrod, M.D.¹

Professor of Psychiatry, Weill Cornell Medical College, Faculty at the Columbia Psychoanalytic Center for Teaching and Research and the New York Psychoanalytic Institute

INTRODUCTION

This special research edition of *Psychoanalytic Psychotherapy* comes at an important crossroad for psychoanalysis. Although small groups of clinicians and researchers are moving forward with manualization of psychoanalytic treatments and systematic outcome studies (for example, Milrod et al., 2007; Bateman & Fonagy, 2006; Clarkin et al., 2007; Barkham et al., 1999; Leichsenring et al., 2009), many psychoanalysts remain indifferent or resistant to the need for research or the value of the emerging research literature, despite pleas arguing for its centrality for more than a decade (Milrod & Busch, 2003a; Milrod & Busch 2003b; Fonagy, 2003; Cooper 1993). The paucity of scientifically-credible data that have been collected which carefully evaluates the utility of psychoanalytic interventions for specific psychiatric illnesses is alarming (Gerber et al., 2011). Outside of this insular field, psychoanalytic treatments are increasingly viewed as irrelevant, in large part due to the lack of demonstrated efficacy of these treatment interventions. Without more carefully conducted evaluations of efficacy that can be understood and accepted by clinicians and scientists outside the narrow discipline of psychoanalysis, psychoanalysis and related mental health interventions remain at risk of perishing as treatments for psychiatric and emotional disorders. Such an eventuality would represent a great loss to our patients, and an unnecessary limitation of the breadth of psychoanalysis.

It is therefore so fortunate that at this crucial moment, this edition features two highly informative, exciting papers from the trailblazing and astute group of Lemma, Target and Fonagy, and Gelman, McKay and Marks. They have, with unprecedented foresight, imported a representative, exportable and specific psychoanalytically-based psychotherapeutic intervention into the realm of service research within the Improving Access to Psychological Therapies (IAPT) program in the UK's national public health service. Gaping psychiatric and mental health needs abound in communities of underserved patients around the globe (Chiu et al., 2005), and until very recently it has not seemed likely that psychoanalysts were willing or able to contribute to this challenging problem. This worry still remains, as research from within psychoanalysis that specifically addresses salient public health needs remains sparse, but it is thrilling that such crucial progress has been made by this group of investigators.

The importance of this study, and of Fonagy, Bateman, and Target's broadly focused recent effectiveness interventions across a wide array of domains within the UK and European

¹Dr. Milrod's work is supported in part through NIMH R01 MH70918-01A2

public health services [this includes research initiatives for assessment of outcomes of dynamic treatment of eating disorders and borderline personality disorder, an intervention study of infants of depressed mothers, a large study of teen depression, a study of the treatment of emotional abuse, a study of parent-infant psychotherapy, a study of psychotherapeutic interventions to target parenting for mothers with personality disorders-to name a few jewels in the crown of this group] cannot be underestimated. These authors have given the psychoanalytic community a roadmap toward the future of the field. And it is bright. Far from the doomsday scenario of increasing marginalization, it seems that with enough innovative, public health-conscious research such as this broad effort, relevant elements of the domain of psychoanalysis may be able to be incorporated into mental health services of the future.

In addition to the overall importance of the public health agenda, the study reported here constitutes an excellent demonstration of core fundamental benchmarks for psychoanalytic research: 1. the adaptation of a psychoanalytic approach to a specific disorder and population of patients, 2. the development of a treatment manual that allow for both treatment adherence assessment and the capacity to reliably train others, 3. the utilization of research as a tool to clarify and refine what we are delivering in our treatments. While such efforts have been the tradition of other tested and now EBM-accepted psychotherapies (CBT, IPT), psychoanalysts have long resisted such specificity and manualization out of concern about disrupting psychoanalytic approaches by rigidifying or narrowing them (Blatt 2001; Busch et al., 2009). In fact, as these papers and others show, research efforts have led to the creative development of well described treatments that demonstrate how we can best tailor our psychoanalytic approaches to short term treatments and specific disorders (e.g., borderline personality disorder, depressive disorders, panic disorder).

While we would like to simply focus on the excitement surrounding these research efforts, we find it necessary to call attention to the ongoing resistance to psychoanalytic research, in an effort to intensify interest and participation of a broader range of psychoanalysts in research. The problem remains that critical scientific evaluation of the utility of psychoanalytic treatments has lagged far behind the evaluation of other forms of psychiatric and psychological treatment interventions (Gerber et al, 2011). The relative dearth of a research agenda within psychoanalysis has derived in part out of the field's collective mistrust of manualization and research tools (Busch et al., 2009). This editorial will first describe the relative paucity of adequate research in psychoanalytic treatments, discuss the sources of resistance amongst psychoanalysts to such research, and then highlight the growing value of this research.

A DEARTH OF RANDOMIZED CONTROLLED TRIALS

Relatively few studies and exceedingly limited systematic evidence has been collected to date that adequately evaluates the utility of psychoanalytic psychotherapy or psychoanalysis. Research studies using designs other than randomized controlled trials (RCTs) may be interesting and informative in other domains, yet they cannot address the fundamental question of efficacy, which can only be determined by comparing treatments in an RCT design (Jadad, 1998). The tools of psychotherapy research are becoming more sophisticated as the field evolves, and for psychoanalysis to survive as a mental health discipline, it is essential for the field that it fosters rigorous scholarship in this area.

Fortunately, there has been notable progress on this front in the past two decades (Fonagy, 2002). Some prominent members of the psychoanalytic research community have begun to embrace outcome research constructively: the American Psychoanalytic Association has awarded partial funds to begin to perform a pilot randomized controlled trial of

psychoanalysis in comparison with supportive expressive psychotherapy and CBT for chronic depression (Roose, 2007), and a few psychoanalytic and psychodynamic teams of researchers have been evaluating psychoanalytically-derived therapies for a variety of psychiatric disorders (for example, Milrod et al., 2007; Bateman & Fonagy, 2006; Clarkin et al., 2007; Barkham et al., 1999; Leichsenring et al., 2009). These are heartening developments.

Nonetheless, efficacy research in psychoanalysis and psychodynamic psychotherapy remains limited. Gerber et al (2011), in an exhaustive systematic review, conducted with experts across multiple domains of interventions research, were able to identify **only 94** randomized controlled trials of any form of psychoanalytically-oriented psychotherapy for any specific set of *a priori* defined psychiatric or emotional problems, in the period between 1974 and 2010. RCTs are widely accepted in medicine as the “gold standard” for the assessment of treatment efficacy, and there is good conceptual agreement about what constitutes a scientifically-credible study (Jadad, 1998). The CONSORT (Consolidated Standards of Reporting Trials) Statement, which has been adopted by most major medical journals, identifies 22 elements important in reporting randomized controlled trials (Moher et al., 2001). The 94 existing psychodynamic studies showed a wide range of methodological levels of rigor. Some of these studies conform to scientific standards. Many of these studies do not meet the ever-more rigorous standards (appropriately) applied in the field of psychotherapy outcome research.

No efficacy studies of psychoanalysis have been completed to date; thus the utility of psychoanalysis *per se* as a treatment for any disorder, from a medical/psychiatric standpoint, is entirely unknown. Given the time, cost, and intensity of the demands placed on patients and therapists who enter into psychoanalysis, the fact that the field has neglected to perform appropriate assessments of whether or not the treatments we routinely recommend and deliver actually work is shocking. Psychoanalysts entering or graduating training, as well as their prospective patients, bear the burden of this failure, as psychoanalysis is rarely considered to be a treatment of choice for any mental or emotional problem in the current health care climate, in part due to the availability of many well studied treatments with demonstrated efficacy.

CLINICAL LORE AND CLINICAL OBSERVATION: A BELIEF IN THE EFFECTIVENESS OF PSYCHOANALYTIC TREATMENTS

How can a field packed with highly erudite, thoughtful clinicians and scholars, dedicated to helping patients change, remain so fixed in obdurate resistance to systematic research? The argument that “absence of evidence does not equal evidence of absence” (Gaskill, 1976), originally coined to justify belief in a superior, supernatural being among the religious, and common in the 1970’s among psychoanalysts to justify continued usefulness of psychoanalysis, is no longer acceptable in defending the lack of an evidence base within psychoanalysis. The public has appropriately come to expect an objective evaluation of the effects (both positive and negative) of any medical or psychiatric intervention that shoulders the responsibility of caring for the sick.

We posit that one core aspect of psychoanalysts’ resistance to research is their belief in the effectiveness of their treatments (Busch et al., 2009). Since they believe that they observe the processes that form the core of psychoanalytic treatments and the responsiveness and clinical improvement of patients, the theory and treatment must perforce be correct, and further study and research do not appear to be necessary. In addition, clinical observation is linked with a large body of literature describing multiple successes of psychoanalysis. Finally, psychoanalysts interact with a wide circle of intelligent and thoughtful clinicians

who also present and discuss their successful cases. Thus clinical lore, collegial interaction, and direct observations by sole practitioners can appear superficially rational as a basis for determining the effectiveness of a treatment.

However, clinical lore and observation can be highly biased, as the subjectivity of the observer can override an accurate assessment of a patient's improvement. Immersion in one method can leave individual practitioners unschooled in differences observable between therapeutic approaches. Psychoanalysts pride themselves on their awareness of the impact of fantasy and wishful thinking during their treatments, but minimize the impact of such factors on their subjective assessment of their own clinical outcomes. Identification with powerful and respected leaders and theoreticians in the field can color a more objective assessment of treatment effectiveness. In our wish to be therapeutic and our belief in our treatment, it is all too easy to disregard patients who were treatment failures, or obtained little benefit from a lengthy and time/cost intensive treatment. Cooper (1993) refers to the historical belief in leeches as an effective intervention for medical disorders as widely disparate as pneumonia and jaundice as a parallel example of the inherent problem of such thinking. Although enough data have been obtained to assure us that psychoanalytic approaches are likely not in this category, appeal to clinical lore and a strong belief in our approaches remain a central inherent problem in the culture of psychoanalysis.

In addition to the bias of clinical belief, the limited sample of patients seen by any individual clinician can interfere with determination for what types of patients the treatment is or is not effective. Psychoanalysts are particularly vulnerable to this phenomenon, as the number of cases they treat is by necessity limited by the length and intensity of the treatments they offer. Furthermore, because of the wide clinical disparity between "psychoanalysis" or "psychoanalytic psychotherapy" as practiced by different individual clinicians, patients being treated in modalities with these monikers are likely to have very different clinical experiences (Milrod 1996). Also, at least for many years, the patients that psychoanalysts treated included a largely-self-select group that presented to psychoanalysts in part out of an interest in this treatment, limiting generalizability of individual psychoanalysts' experiences further. Finally, many psychoanalysts continue even now to avoid clearly defining the diagnoses of patients they treat or to use less generally-accepted diagnostic tools than the DSM (American Psychiatric Association, 2004). These idiosyncrasies make it difficult to determine, even in direct clinical observation, which specific patients respond to which specific forms of psychoanalytic treatment. Over the years the need to tailor psychoanalytic treatments for patients with specific disorders has become apparent, but the study of which patients require what kinds of modifications is in its infancy.

Although psychoanalysts, like most other practitioners, want to believe that the positive effects of their treatments are the result of their specific psychoanalytic interventions, many other factors complicate this assessment within individual cases. A notable factor is the placebo effect (Benedetti et al., 2005), which has been found to be high in the treatment of some psychiatric disorders, and constitutes a key basis for the need for placebo controlled studies. Also, so-called nonspecific factors in psychotherapy have been found to be responsible for a significant percentage of the outcome of treatment (Frank & Frank, 1991). These include: affective arousal, feeling understood by therapist, development of a framework for understanding (therapeutic rationale), a sense that the therapist is an expert, the ritual of the therapeutic procedure, and the therapeutic alliance.

Confronted with the pressure to perform psychoanalytic research and the many realistic difficulties with this endeavor, psychoanalysts have resorted to a counter-productive series of efforts to claim that such research is unnecessary or not useful, or that adequate psychoanalytic research has already been accomplished, or that studies of psychoanalysis

cannot be conducted in analogous ways as studies of other forms of psychosocial interventions. None of these claims are accurate. Guided by the belief in the effectiveness of their treatments, psychoanalysts have seized on the idea that research accomplished on other treatments is wrongheaded or not appropriate for psychoanalytic interventions (Busch et al., 2009). Manuals have been criticized as potentially being too rigid, interfering with exploration or the psychoanalytic process (Blatt 2001). In actuality, a strength of psychoanalytic treatment manuals to date is that they allow a wide range of latitude and flexibility in therapeutic delivery to address problems in a way that is tailored to individual patients. Those with training in psychoanalysis or psychoanalytic approaches have found these treatment manuals to be consistent with their own clinical practice (Gelman et al.; Busch et al., 2003; Busch et al., 2009). Realistic limitations of efficacy studies, including relative homogeneity of groups, exclusion of some complex patients, and the need to operationalize treatments, have been used to justify a failure to pursue outcome research.

Another counter-productive approach to the problem of the limited available psychoanalytic outcome research data has been to seize upon the small body of research that has been accomplished as evidence of the effectiveness of psychoanalytic treatments in general. Thus, there has been excessive focus on carefully crafted “meta-analyses” (Driessen et al., 2010; Leichsenring et al., 2004; Leichsenring & Rabung, 2008). No amount of complex and careful the statistical modeling used in meta-analyses can substitute for scientifically-credible data acquired from RCTs. Many of the studies employed in meta-analyses contain significant methodological flaws (Gerber et al., 2011), and hence cannot shed light on problems of therapeutic response, particularly with pooled data.

CONCLUSION

It is time to relinquish our magical wish that the clinical efforts of a highly trained group of clinicians can claim effectiveness of a set of treatments based on clinical experience, training, experience, and literature. The few RCTs that have been conducted to date are grossly inadequate to assess the vast swath of psychoanalytic treatments that continue to be delivered, albeit less frequently than in the past. Carefully conducted efficacy research is a necessity for the appropriate assessment of any treatment, and it is essential for the survival of our field.

In addition, as the papers of Lemma et al and Gelman et al demonstrate, psychoanalytic research yields a swath of benefits in addition to essential efficacy studies. These include the development of psychoanalytic treatments tailored for use in specific disorders, such as Dynamic Interpersonal Therapy (Lemma et al) for treatment of depression, panic focused psychodynamic psychotherapy (Milrod et al., 1997), and mentalization based and transference focused psychotherapies for borderline personality disorder. Manualization of treatments, rather than rigidifying psychoanalytic approaches, has led clinicians and researchers to define and illustrate more clearly what they do in their treatments. As Gelman et al. note: “...what DIT really helped us with was in focusing the focus – having some way to think in a structured and theoretical way about the direction of our interventions.” In these manualized treatments modifications of psychoanalytic techniques have been developed to more effectively and rapidly relieve patients of symptoms and distress. Thus research provides the opportunity to refine, clarify, and more clearly communicate what we do in our treatments, expand the range of patients we can treat, and more accurately assess whether we are helping our patients to improve. Furthermore, with efforts such as those exemplified by Lemma et al, we have the potential of providing relief to a wide array of patients in the community who heretofore may not have even had the option of being in any psychotherapy at all.

References

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision. American Psychiatric Association; Washington, DC: 2000.
- Barkham M, Shapiro DA, Hardy GE, Rees A. Psychotherapy in two-plus-one sessions: outcomes of a randomized controlled trial of cognitive-behavioral and psychodynamic-interpersonal therapy for subsyndromal depression. *J Consult Clin Psychol*. 1999; 67:201–211. [PubMed: 10224730]
- Bateman A, Fonagy P. 8 Year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. *American Journal of Psychiatry*. 2008; 165:631–638. [PubMed: 18347003]
- Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. *J Neurosci*. Nov 9; 2005 25(45):10390–402. [PubMed: 16280578]
- Blatt SJ. The effort to identify empirically supported psychological treatments and its implications for clinical research, practice, and training: Commentaries on papers by Lester Luborsky and Hans H. Strupp. *Psychoanalytic Dialogues*. 2001; 11:635–646.
- Busch FN, Milrod BL, Rudden M, Shapiro T, Roiphe J, Singer M, Aronson A. How Treating Psychoanalysts Respond to Psychotherapy Research Constraints. *J Amer Psychoanal Assn*. 2001; 49:961–983.
- Busch FN, Milrod BL, Sandberg LS. A study demonstrating efficacy of a psychoanalytic psychotherapy for panic disorder: implications for psychoanalytic research, theory, and practice. *J Am Psychoanal Assoc*. 2009; 57(1):131–148. 2009. [PubMed: 19270248]
- Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*. Jun; 2005 62(6):617–27. [PubMed: 15939839]
- Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: A multiwave study. *Am J Psychiatry*. Jun.2007 164:922–928. 2007. [PubMed: 17541052]
- Cooper AM. Discussion: On Empirical Research. *J Amer Psychoanal Assn*. 1993; 41:381–392.
- Driessen E, Cuijpers P, de Maat SC, Abbass AA, de Jonghe F, Dekker JJ. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. *Clin Psychol Rev*. Feb; 2010 30(1):25–36. [PubMed: 19766369]
- Fonagy P. An Open Door Review of Outcome Studies in Psychoanalysis Report for the IPA. 2002.
- Fonagy P. Genetics, developmental psychopathology, and psychoanalytic theory: the case for ending our (not so) splendid isolation. *Psychoanalytic Inquiry*. 2003; 23:218–248.
- Frank, JD.; Frank, JB. *Persuasion and Healing*. 3rd Edition. Johns Hopkins University Press; Baltimore: 1991.
- Gaskill HS. An assessment of psychoanalysis as viewed from within. *J Am Psychoanal Assoc*. 1976; 24(3):553–88. [PubMed: 787056]
- Gerber A, Kocsis J, Milrod B, et al. A Quality-Based Review of Randomized Controlled Trials of Psychodynamic Psychotherapy American. *Journal of Psychiatry*. 2011
- Jadad, A. *Randomised controlled trials*. BMJ Books; London: 1998.
- Leichsenring F, Rabung S. Effectiveness of Long-term Psychodynamic Psychotherapy: A Meta-analysis. *JAMA*. 2008; 300:1551–1565. [PubMed: 18827212]
- Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. *Arch Gen Psychiatry*. 2004; 61(12):1208–16. [PubMed: 15583112]
- Leichsenring F, Salzer S, Jaeger U, Kächele H, Kreische R, Leweke F, Rüger U, Winkelbach C, Leibing E. Short-Term Psychodynamic Psychotherapy and Cognitive-Behavioral Therapy in Generalized Anxiety Disorder: A Randomized, Controlled Trial. *Am J Psychiatry*. 2009; 166:875–881. [PubMed: 19570931]
- Milrod B. Anxiety as Symptom and Signal, Book Review. *Int. J. Psychoanalysis*. 1996; 77:850–853.
- Milrod B, Busch F. Prologue to Psychoanalytic Research: Current Issues and Controversies. *Psychoanalytic Inquiry*. 2003; 23:211–217.

- Milrod BL, Busch FN. Epilogue to Psychoanalytic Research: Current Issues and Controversies. *Psychoanalytic Inquiry*. 2003; 23:405–408.
- Milrod B, Leon AC, Busch FN, et al. A Randomized Controlled Clinical Trial of Psychoanalytic Psychotherapy for Panic Disorder. *American Journal of Psychiatry*. 2007; 164:265–272. [PubMed: 17267789]
- Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA*. 2001; 285(15):1987–91. [PubMed: 11308435]
- Roose, S. The COPP study, grant to the American Psychoanalytic Association. 2007.